Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

Overview of attention for article published in Respiratory Research, February 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 23 X posts from 21 X users, with an upper bound of 77,411 followers.

Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chro…https://t.co/fycK1eGA3H

RT @atscommunity: Roflumilast can be considered as an alternative therapy in certain #COPD patients: https://t.co/7VrNr9Uwoy

RT @atscommunity: Roflumilast can be considered as an alternative therapy in certain #COPD patients: https://t.co/7VrNr9Uwoy

RT @atscommunity: Roflumilast can be considered as an alternative therapy in certain #COPD patients: https://t.co/7VrNr9Uwoy

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 19 additional X posts.